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 Abstract 
The most recent genome-wide association study in amyotrophic lateral sclerosis 
(ALS) demonstrates a disproportionate contribution from low-frequency variants to 
genetic susceptibility of disease. We have therefore begun Project MinE, an 
international collaboration that seeks to analyse whole-genome sequence data of at 
least 15,000 ALS patients and 7,500 controls. Here, we report on the design of 
Project MinE and pilot analyses of newly whole-genome sequenced 1,264 ALS 
patients and 611 controls drawn from the Netherlands. As has become characteristic 
of sequencing studies, we find an abundance of rare genetic variation (minor allele 
frequency < 0.1%), the vast majority of which is absent in public data sets. Principal 
component analysis reveals local geographical clustering of these variants within 
The Netherlands. We use the whole-genome sequence data to explore the 
implications of poor geographical matching of cases and controls in a sequence-
based disease study and to investigate how ancestry-matched, externally sequenced 
controls can induce false positive associations. Also, we have publicly released 
genome-wide minor allele counts in cases and controls, as well as results from genic 
burden tests. 
 
 
  
.CC-BY-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/152553doi: bioRxiv preprint first posted online Jun. 20, 2017; 
 Introduction 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing, fatal neurodegenerative 
disease.1 Twin studies estimate the heritability of ALS to be ~60%, suggesting a 
strong genetic component contributing to disease risk,2 and approximately 10-15% of 
patients have a clear family history of disease.3 Genetic risk factors have been 
extensively studied in familial ALS cases, and this effort has led to the identification 
of highly penetrant causal mutations, including mutations residing in SOD1,4 
TARBP,5 FUS,6 and C9orf72.7,8 In so-called sporadic ALS cases, who have no 
known family history of disease and comprise the majority of all cases, only a small 
number of other common genetic risk loci have been identified. Among these loci are 
the ATXN2 CAG repeat expansion,9 mutations in C21orf2,10 common variation within 
the UNC13A,11 SARM1,12 MOBP,10 and SCFD110 loci and, most importantly, the 
highly pathogenic C9orf72 repeat expansion. The latter highlights the typical 
categorization of “familial” and “sporadic” ALS as likely non-distinct groups with 
overlapping genetic architectures. 
Despite these recent advances in ALS genetics, the bulk of risk loci in ALS remain 
undiscovered. The most recent and largest ALS GWAS, performed in 12,577 cases 
and 23,475 controls, showed a disproportionate contribution of low-frequency 
variants to the overall risk of ALS.10 Genome-wide association studies to date have 
focused almost exclusively on common variation (minor allele frequency > 1%), 
leaving lower-frequency and rarer variants segregating in the general population 
essentially untested. Thus, there is a pressing need to study rare variation across the 
full length of the genome in cases with and without family history of disease. To this 
end, we have begun Project MinE, a large-scale whole-genome sequencing study in 
ALS. The project leverages international collaboration and recent developments in 
sequencing technologies, allowing us to explore the full spectrum of genetic variation 
in samples collected worldwide. Project MinE seeks to obtain sequencing data in 
15,000 ALS patients and 7,500 matched controls with the aim of identifying new loci 
associated to ALS risk, fine-map known and novel loci, and provide the ALS 
community (and the disease research community at large) with a publicly-available 
summary-level dataset that will enable further genetic research of this and other 
diseases. A data access committee controls access to raw data, ensuring a FAIR 
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 data setup (http://www.datafairport.org). 
While common variant association studies have become mostly standardized over 
the last decade, rare variant association studies such as Project MinE face an array 
of new challenges. Sequencing studies demand large sample sizes to detect small 
effects at rare variants, thus making large-scale collaborative consortia a necessity. 
Sequence data itself, measuring into the terabytes, poses a substantive data 
storage, processing, and management challenge. The analytic effects of (tight) 
spatial clustering of rare variants is not yet well understood,13,14 making careful 
case/control selection and proper handling of population stratification key. Rare 
variant association studies typically employ genic burden testing to overcome power 
problems, thus requiring a series of analytic choices be made regarding the 
functional annotation15 and statistical analysis of the data. Here, we discuss the “pilot 
phase” of Project MinE, performed in 1,264 cases and 611 controls collected in the 
Netherlands. Though the sample size is too small to detect moderate-effect genetic 
associations, it allows us to explore the implications of these many analytic 
challenges faced by Project MinE or any disease study employing sequence data, to 
understand the genetic basis of disease. We outline the formation of the consortium, 
study design challenges, data quality control and analysis approaches employed by 
the project, and publicly release all minor allele counts in cases and controls together 
with results from genic burden tests derived from this dataset.   
 
  
.CC-BY-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/152553doi: bioRxiv preprint first posted online Jun. 20, 2017; 
 Material and methods 
Consortium design 
The MinE consortium includes ALS research groups from 16 different countries 
collaborating in a “franchise” design (www.projectmine.com, Figure 1). This design 
means that samples and sample-affiliated data (e.g., dense phenotyping) from 
partners are collected, processed and stored according to the same protocol, while 
partners maintain full control over their samples, affiliated data, and any additional 
data generated on those samples. Within the consortium, ALS patients and controls 
are ascertained through clinics affiliated to the research groups. At these clinics, 
neurologists obtain a standardized core clinical data set with phenotypic information 
(Supplementary Table 1) and blood is drawn for DNA isolation. DNA samples are 
stored on site, but are collectively prepared for sequencing at commercial 
sequencing providers, in batches of up to 1,000 samples. The consortium continues 
to expand, welcoming research groups who wish to dedicate time and raise money 
to understand the genetic and environmental underpinnings of ALS.  
A number of variables, including pricing for varying numbers of genomes, DNA input 
requirements, availability of PCR-free library preparation, and methods for data 
delivery, were all considered during selection of a sequencing provider 
(Supplementary Table 2). The majority of the data to date have been sequenced at 
Illumina (San Diego, CA, USA); a small subset is currently being sequenced locally 
in Australia and Canada. From Illumina, the data are transferred through the internet 
(via a secure connection) to SURFsara (Amsterdam, The Netherlands). After arrival, 
the data is automatically checked for corruption and stored in duplicate on two 
geographically separated tape silos. The storage system is connected to a 
distributed parallel file system (dCache16) that provides high performing file service to 
a 5,600 core high-throughput computing cluster. 
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Figure 1 Consortium design. Consortium structure including funding agencies, research groups, the Project 
MinE general assembly, sub-projects, and data management. Each research group obtains funding using 
uniform grant proposals shared between the research groups. DNA samples are provided to the sequencing 
providers via the Project MinE general assembly so research groups can profit from a lower pricing scheme 
available when large numbers of DNA samples are provided together. Samples are sequenced, and data (whole-
genome sequence data in raw and genotype-called format, SNP array data, and methylation array data) is 
centrally stored (the size of the data for the first 1,935 samples is indicated in parentheses; the full dataset for N 
= 22,500 samples will be ~1.7 petabytes). External data can also be contributed to and integrated into the 
dataset. Different research groups, including external groups, collaborate to work on specific projects. After 
review of the project proposal to the general assembly, researchers working on these projects will be granted 
access to the data and may also use the central ICT facilities. ALS: amyotrophic lateral sclerosis, WGS: whole 
genome sequencing. 
 
From here, consortium members can access the genomes of their samples and ask 
that their data be additionally backed up on the High Performance Compute cluster 
at the University Medical Center Utrecht (Utrecht, The Netherlands). Analysis teams 
(possibly including researchers from external groups) can submit analysis proposals 
to the consortium and then gain access to all genomes and make use of the 
SURFsara compute facilities (Figure 1). Access to the data or usage of the compute 
facilities is contingent on (a) X.509 authentication certificates and (b) proposed 
analyses for the data. This data infrastructure allows, for example, particular cohorts 
and individuals access to particular subsets or all of the data, depending on the 
analysis. Based on permission given by the manager of the data (i.e., the principal 
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 investigator of the contributing research group), access is provided through the 
gridftp protocol v2 that is tailored for large and reliable file transfers. The X.509 
certificates allow for the possibility to scale out to other compute facilities; given valid 
credentials, the data can then be accessed from anywhere. 
Sample selection 
Patients were diagnosed with definite, probable, and probable lab-supported ALS 
according to the revised El Escorial Criteria.17 For the pilot analyses presented here, 
all patients were seen by neurologists specialized in motor neuron diseases at the 
University Medical Center Utrecht and Academic Medical Center (Amsterdam, The 
Netherlands). The samples were all included in the Prospective ALS study in the 
Netherlands (PAN), an incidence-based registry of ALS cases18. Controls were 
population-based controls that were matched for age, sex, and geographical region. 
As is true for all contributing cohorts to Project MinE, cases and controls were 
ascertained in a roughly 2:1 ratio; the 2:1 case-control ratio was selected to improve 
detection of variants in cases and with the plan to include publicly-available 
sequenced controls in future analyses. 
Phenotypic information 
For all participants in Project MinE, we have defined a core clinical dataset, meant to 
be collected and made available for all cases (Supplementary Table 1). Phenotypic 
information is stored physically separately (https://euromotor.umcutrecht.nl) from the 
genetic data in a clinical database called Progeny. The phenotypic and genetic data 
can be connected through sample identifiers. Phenotypic data storage is organized 
similarly to the sequencing data: every contributing group has default full access to 
their own phenotypic data, but data can easily be jointly shared analysed if desired. 
This core clinical dataset (Supplementary Table 1) includes date of birth, sex, site 
of onset (spinal or bulbar), date of disease onset, diagnostic category (according to 
both revised and original El Escorial scoring), Forced Vital Capacity at time of 
diagnosis, cognitive status measured by the Edinburgh Cognitive and Behavioural 
ALS Screen (ECAS), and a revised ALS functional rating scale score (ALSFRS-R).19 
The required endpoint data include date of death, date of starting invasive ventilation 
or requiring continuous non-invasive ventilation. For the pilot data used in this study, 
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 we obtained additional information on place of birth through the Dutch Municipal 
Personal Records Database. 
Whole-genome sequencing 
Venous blood was drawn from patients and controls from which genomic DNA was 
isolated using standard methods. We set the DNA concentrations at 100ng/ul as 
measured by a fluorometer with the PicoGreen® dsDNA quantitation assay. DNA 
integrity was assessed using gel electrophoresis. All samples were sequenced using 
Illumina’s FastTrack services (San Diego, CA, USA) on the Illumina HiSeq 2000 
platform. Sequencing was 100bp paired-end performed using PCR-free library 
preparation, and yielded ~40x coverage across each sample. The Isaac pipeline20 
was used for alignment to the hg19 reference genome as well as to call single 
nucleotide variants (SNVs), insertions and deletions (indels), and larger structural 
variants (SVs). Both the aligned and unaligned reads were delivered in binary 
sequence alignment/map format (BAM) together with variant call format (gVCF) files 
containing the SNVs, indels and SVs.20  gVCF files were generated per individual 
and variants that failed the Isaac-based quality filter were set to missing on an 
individual basis. 
Data analysis 
Quality control. Quality control (QC) of the data included QC at an individuals and 
variant level. Full details of QC are provided in the supplement. 
Principal component analysis. Principal components were calculated for all 
individuals including variants at different allele frequency thresholds using GCTA.21 
The eigenvectors of the first twenty principal components were regressed on latitude 
and longitude of birthplace. In a leave-one-out scheme, this linear model was used to 
predict the birthplace for the individual left out. 
Identity-by-descent analysis. We phased all non-singleton variants using SHAPEIT222 and 
then used BEAGLE423 to detect runs of identity-by-descent (IBD) between individuals. 
Association analysis. Genotypes at common variants (MAF > 0.5%) were tested for an 
association with case/control status using logistic regression (PLINK v1.9)24,25 assuming an 
additive model. Optionally, the first 10 principal components (PCs) were included as 
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 covariates. To test rare variation, we performed genic “burden” testing. All variants were 
functionally annotated using ANNOVAR26. We then determined three functional groups for 
gene-based association testing: (a) loss of function (LOF) mutations (premature stop 
mutations, stop-loss mutations, mutations at splice sites, and frameshift indels), (b) 
nonsynonymous mutations, and (c) LOF and nonsynonymous mutations (aggregated). 
Burden testing (T1, T5, Variable Threshold, Madsen-Browning and SKAT) was implemented 
using ScoreSeq27 and performed across all variants with MAF < 5%. All burden tests were 
adjusted for sex and the top ten PCs and performed on the QC-passing set of unrelated 
samples (1,169 cases and 608 controls).  
Population stratification and externally sequenced controls. To assess the type I 
error in a burden testing framework, we simulated 100 different phenotypes for two 
scenarios: perfect matching and imperfect matching with a North-to-South gradient 
for the number of cases (keeping the case/control counts the same, Supplementary 
Figure 1), and then performed burden testing on LOF and nonsynonymous 
mutations with and without principal components as covariates. The most extreme p-
value from each simulation was extracted (resulting in 100 extreme p-values total, 
per scenario); the fifth-most extreme p-value represented the p-value threshold 
necessary to maintain study-wise type I error at 5%. Subsequently, we assessed the 
impact of including ancestry-matched, externally sequenced controls (the Genome of 
the Netherlands, GoNL14) instead of controls sequenced as a part of Project MinE. As 
their data is mostly available formatted as VCF files, we combined both datasets on 
a VCF level, without realignment or joint variant calling. The structure of this dataset 
was described by principal component analysis and we assessed inflation of the test 
statistics when externally sequenced controls were included in genome-wide burden 
testing. 
Study approval and informed consent 
All participants gave written informed consent and the institutional review board of 
the University Medical Center Utrecht approved this study. Additional approval was 
obtained to access the Dutch Municipal Personal Records Database. 
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 Results 
Baseline characteristics and description of data 
After quality control, 1,169 unrelated Dutch-ancestry cases and 608 ancestrally-
matched controls were available for analysis. Their baseline characteristics are 
displayed in Table 1 and the distribution of cases and controls throughout The 
Netherlands is displayed in Figure 2a. In total, 42,200,214 SNVs and indels passed 
quality control. The majority (69%) of these sequenced variants were rare (MAF < 
0.001, < 3 allele observations in our dataset, Supplementary Figure 2). In 
particular, the bulk of these rare variants were not observed in publicly available 
datasets of whole-genome sequencing data including the Genome of The 
Netherlands project (GoNL release 5 from 28-10-2013, N = 498) and the 1000 
Genomes Project (Phase 1 from 23-11-2010, N = 1,093). This observation reflects 
population-specific variants and the growing number of rare variants that will 
continue to be discovered as sequencing is performed in increasingly larger samples 
around the globe. As expected, most common variants (MAF > 1%) have been 
observed in these two datasets (97.5% in GoNL and 98% in the 1000 Genomes 
Project) reflecting global sharing of common variation. 
Geographic clustering 
The first and second principal components reflected the geographical distribution of 
cases and controls in detail (Figure 2b). The eigenvectors of the first principal 
component explained 55% of the variance in latitude (p = 8.4 × 10-284) and the 
second principal component explained 24% of the variance in longitude (p = 1.7 × 
10-107) of the geographical distribution of the samples across the Netherlands. 
Prediction models including the first twenty principal components predicted the 
birthplace of individuals with high accuracy (Supplementary Figure 3). The 
accuracy increased when including rarer variants; the median distance between the 
predicted and actual birthplace decreased from 50 kilometres (31 miles) when 
considering common variants (MAF > 0.1), to 36 kilometres (22 miles) when 
including rarer variants (MAF > 0.001), illustrating the strong geographical clustering 
of rare variants.28  
.CC-BY-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/152553doi: bioRxiv preprint first posted online Jun. 20, 2017; 
  
Figure 2 Population structure by principal component analysis. (a) Birthplaces of cases and controls for 
individuals born in The Netherlands. (b) The first two principal components reflect the geographical distribution 
of samples. Individuals are shaded by province of birth as shown in panel (a). The first principal component is 
strongly correlated with birthplace latitude (p = 8.4×10-284) and the second principal component with longitude (p 
= 1.7×10-107). (c-e) Relation between birthplace distance between pairs of individuals and shared IBD segments 
1-2 cM (c), 2-7 cM (d) and 7-15 cM (e). Long IBD segments are, as expected, mostly shared by individuals born 
close to one another. PC: principal component, MAF: minor allele frequency, km: kilometer, cM: centimorgan. 
 
Sharing of IBD segments showed strong geographical patterns throughout the 
Netherlands. As was observed in a previous population genetics study in The 
Netherlands there is a clear North-to-South gradient for sharing of shorter (and thus 
older) IBD segments (Supplementary Figure 4a). We also confirmed the finding 
that people born in the Southern provinces shared more of these IBD segments with 
people from the Northern provinces than they share with people within their own 
province, reflecting the previously described complex migration patterns14. Sharing of 
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 longer IBD segments, reflecting more recently shared ancestry, was highly 
dependent on the distance of birthplaces between individuals (Figure 1c-e and 
Supplementary Figure 4b). 
Association testing in ALS cases and controls 
We found no variants reaching genome-wide significance (p = 5.0 × 10-8) with ALS in 
our sample, as expected given the sample size. We looked up known associated 
single-variants, three of which showed nominal association to the trait (p < 0.05, 
Supplementary Table 1). Similarly, no loci achieved exome-wide significance in 
burden testing (p ≈ 5.0 × 10-7, after adjusting for 20,000 tested genes, the various 
burden test types, and sets of SNPs tested; Supplementary Figure 5) due to limited 
power (Supplementary Figure 6). Burden testing p-values for all genes tested can 
be found at http://databrowser.projectmine.com/. 
The implications of study design 
We sought to evaluate how matching cases and control, thereby introducing fine-
grained population structure, influenced the burden testing type I error rate. 
Therefore, we simulated phenotypes that (1) created perfectly geographically 
matched case-control sets and (2) introduced population structure between patients 
and controls (Supplementary Figure 1). We subsequently ran simulations that did 
not correct for any covariates or those that included common-variant (MAF > 0.1%) 
principal components. Imperfect matching did not yield a markedly more stringent p-
value to maintain a study-wide type I error at 0.05 for all burden tests (Table 2), likely 
due to limited power. Correcting for PCs did not affect the p-value to maintain study-
wise type I error at 0.05 either. 
To test the analytic implications of a study design that uses its resources solely for 
the sequencing of cases and collects controls from an external source, we merged 
genotypes from the ALS cases with Dutch-ancestry samples whole-genome 
sequenced as part of the Genome of the Netherlands (GoNL) project.14 Principal 
component analysis indicated a clear separation of the two projects, where PC1 
effectively captured each project (Supplementary Figure 7a). Removal of highly 
differentiated SNPs with a frequency difference > 5% across the two projects 
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 somewhat mitigated this separation (Supplementary Figure 7b).  As expected, 
single-variant testing between ALS cases and GoNL controls revealed excessive 
genomic inflation (  = 1.12). Similarly, burden testing comparing ALS cases and 
GoNL controls revealed a strongly inflated QQ plot and genomic inflation factor (  = 
2.49), demonstrating the challenges of using externally sequenced controls to 
identify disease genes in a separately-sequenced set of cases and controls. 
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 Discussion and future perspectives 
Family-based and population-level genetic studies have revealed ALS as a complex 
disease with a distinct role for rarer genetic variation. Although numerous genetic 
variants have been identified as conferring ALS risk, the genetic basis in the vast 
majority of cases is not yet understood. Here, we have described the design and 
pilot analyses of a large-scale whole-genome sequencing study aimed at discovering 
new genetic risk factors and further elucidating the genetic basis of ALS.  
Data sharing and open-access science 
Data sharing and transparency in scientific research is advantageous for a host of 
reasons: it allows for analyses across large sets of samples, particularly for lower-
prevalence diseases such as ALS; ensures rigorous experiments that can be 
reproduced by external groups; and allows for publicly-funded research to be made 
available to the public itself. Project MinE cannot publicly release individual-level 
genotype data due to consent. However, genotype frequency information and genic 
burden testing results are publicly available at the project’s online browser 
(http://databrowser.projectmine.com/). This browser will be continuously updated as 
the project expands, and will provide more detailed data integration in future 
releases. To further enhance the transparency within the consortium itself and with 
external collaborators and researchers, the project has begun a GitHub repository, to 
share and maintain scripts and data processing pipelines.  
The advantages of ‘franchising’ 
Given the relatively low prevalence of ALS, international collaboration is crucial to 
assembling large samples. Thus far, the “franchise” design of our consortium has 
allowed us to rapidly expand to sixteen participating research groups globally. This 
joint effort has collected enough resources to sequence >7,000 samples, with more 
currently being collected. Ongoing analyses include case-control association testing, 
as well as association testing in age-of-onset, and survival time. Additionally, the 
available core clinical dataset, uniformly collected for all individuals included in 
Project MinE, will allow for a host of other discovery analyses. 
Study design implications: data management, population architecture, and external 
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 controls 
The pilot analyses, though small in sample size, yield several immediate and 
important conclusions. First, while genotype-called data (in VCF format) is easily 
handled by a high-performance compute cluster, whole-genome BAM files 
(approximately 80 gigabytes per genome) demand a compute infrastructure that can 
handle terabytes and even petabytes of data. This includes direct delivery of the 
genomes that are currently being sequenced via a direct high-speed connection 
between the sequencing provider and a computer cluster with a GRID architecture 
(SURFsara). Though some research institutions are already prepared for such a 
deluge of data, others will need to carefully consider compute infrastructure and the 
technical ramifications of assembling big data before embarking on large-scale 
sequencing analyses. Further, having all data stored in a single location enables 
analysis across the full dataset, including on BAM-level data. 
Second, initial quality control of the data suggests that the high-depth sequencing 
and downstream genotype calling is yielding high-quality data, reflected in our ability 
to reconstruct, through principal component analysis and identity-by-descent 
analyses, demographic observations that have been made in separate large-scale 
sequencing efforts in the Dutch population.14 Further, the population analyses 
performed here and in particular the birthplace analysis, highlights the sensitivity of 
genome-wide sequence data. The data must be carefully protected such that those 
who have donated DNA to enable disease research, will also remain anonymous (in 
accordance with the consent provided).29 
Third, the high-resolution geographical clustering of rare variants as observed in 
these analyses could pose challenges in finding rare variants that contribute to ALS 
risk. The commonly applied burden test approach, however, does not seem to suffer 
from increased type I error rates induced by modest imperfections in geographically 
matching samples, as was shown by the burden test simulations. While it is possible 
that aggregating rare variants (found in potentially many geographic locations) in 
these tests makes the approach more robust to population structure, these results 
should be interpreted with caution. The modest power in our pilot sample likely 
limited our ability to detect the increasing type I error rates induced by imperfect 
geographic sample matching. With the increasing number of ancestrally diverse 
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 samples that are being included in Project MinE, false positive associations due to 
population stratification remain a serious concern, especially when our aim becomes 
identifying the causal single variant(s) that drive the genic burden signal. Correcting 
for principal components can help to control type I error, though potentially not 
sufficiently so in burden testing. More sophisticated analytic approaches, such as 
employing a linear mixed model in single variant and genic burden testing, will likely 
be helpful in controlling for population stratification across the full set of Project MinE 
samples.30 
We further demonstrate that inclusion of externally-sequenced samples can pose 
analytical challenges. Specifically, we show that using ancestry-matched controls 
from publicly-available datasets can strongly inflate association test statistics if the 
sequences have not been processed together from BAM-level data. Sequence data 
can contain underlying structure due to sequencing platforms, coverage, alignment 
and calling algorithms. Inclusion of externally sequenced cases and controls 
(sequenced either separately or together) is non-trivial must be approached with 
extreme rigor. Methods for handling the merging and calling of heterogeneous 
sequencing datasets are currently being applied in large consortia31–33 and indicate 
that obtaining a high-quality dataset requires calling genotypes from petabytes of raw 
data in a uniform way across the full set of samples. Additional developments in 
handling heterogeneous sequence data include association testing on read-level 
data to allow for externally sequenced controls.34 Although these methods come with 
significant computational burden, similar approaches could be applied in Project 
MinE, in an effort to expand beyond the 22,500 samples sequenced initially by the 
project. 
The future of Project MinE 
With the veritable explosion in methods and approaches being developed for whole-
genome sequence data analysis, Project MinE will seek to leverage new and 
powerful methods for uncovering ALS risk variants. Current plans include more 
sophisticated functional annotation techniques, such as unsupervised-learning 
approaches to discriminate between functionally relevant and benign variation in the 
genome35,36; implementing a linear mixed model approach to burden testing30; a 
burden testing framework that will focus not only on genes but also on regulatory and 
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 other non-coding elements; and analyses that investigate both variation and 
methylation data. We have additionally established a pipeline to lift all our data to the 
newest genome build (hg38), which will likely yield better coverage of the genome in 
our samples. As the size of the data expands and additional collaborators join the 
effort, we will explore additional data structures that can facilitate transcontinental 
data analysis with minimal physical movement of data.  
Finally, in addition to testing SNVs and indels, we will explore the role of more 
complex genetic variation such as structural variants and repeat expansions, which 
are known to play an important role in ALS susceptibility, yet have never been 
studied at genome-wide scale. With a global collaboration in place, a wealth of 
genetic variation being generated, and new methods for sequence data constantly in 
development, Project MinE will be the largest and most complete study of ALS 
genetics to date, poised to reveal novel risk loci, fine-map known disease genes, and 
shed light on the biological drivers of disease. 
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 Tables 
  ALS Controls 
N 1196 610 
sex, % female 41.1 43.1 
Type   
     familial (%) 31 (2.6) - 
     sporadic (%) 1165 (97.4) - 
C9orf72   
    WT (%) 1095 (91.6) - 
    expanded (%) 74 (6.2) - 
    unknown (%) 27 (2.3) - 
age at onset, years (IQR) 63.97 (56.58 - 70.57) - 
site of onset   
   bulbar (%) 386 (32.3) - 
   spinal (%) 718 (60.0) - 
   thoracic (%) 30 (2.5) - 
   unknown (%) 62 (5.2) - 
survival, years (IQR) 2.29 (1.58 - 3.28) - 
   deceased (%) 966 (80.8) - 
 
Table 1 Baseline characteristics of samples included in Project MinE. WT = wild-type, IQR = interquartile range. 
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 Scenario 1: perfect matching 
 Type I error in burden tests 
 T1 MB VT SKAT 
No PCs 4.25 x 10-6 3.38 x 10-6 3.94 x 10-6 2.35 x 10-6 
Common PCs 2.86 x 10-6 3.99 x 10-6 8.12 x 10-6 2.24 x 10-6 
Scenario 2: imperfect matching 
 Type I error in burden tests 
 T1 MB VT SKAT 
No PCs 4.40 x 10-6 1.90 x 10-5 1.46 x 10-5 6.72 x 10-6 
Common PCs 5.35 x 10-6 9.35 x 10-6 1.04 x 10-9 7.81 x 10-6 
 
Table 2 Populations structure and use of principal components (PCs) to control type I error. No marked 
differences were observed between the p-values in perfect or imperfect matching scenarios (with or without PCs) 
to maintain the study-wise type I error rate at 0.05. Common PCs = principal components calculated on all 
common SNPs (MAF > 0.01). T1, burden test that considers variants with MAF < 0.01; MB, Madsen-Browning 
burden test that inversely weights variants by frequency; VT, Variable Threshold test; SKAT, Sequence Kernel 
Association Test. 
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